PTCE Pharmacy SoundScripts  Listen and learn with PTCE’s accredited audiobooks!
PTCE is the go-to resource for accredited pharmacist-focused CE content. PTCE’s Pharmacy Soundscripts audiobooks allow pharmacists practicing in community, health-system, specialty, managed care, and oncology settings to stay at the forefront of the latest advancements in the health care and pharmacy landscape. Each CE audiobook is a comprehensive recording of PTCE’s printed CE articles, packed with the same valuable information and clinical pearls, conveniently segmented into chapters available on-the-go so you can earn CE credit on your own time. Explore our growing library of CE-accredited audiobooks and discover topics to fit your learning needs and provide the highest quality of pharmacy care to your patients. 
]]> http://www.pharmacytimes.org audioboom.com Wed, 17 Sep 2025 02:08:19 +0000 en https://audioboom.com/i/42075506.png PTCE Pharmacy SoundScripts http://www.pharmacytimes.org false PTCE Pharmacy SoundScripts ceinfo@pharmacytimes.com 4e8b7420-15e4-50c6-abf5-8e6551a89d43 https://audioboom.com/channels/5135386.rss episodic 11: Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC https://audioboom.com/posts/8778075 11 Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC 4368 false full This article will review the role of EGFR-targeted therapies in non-small cell lung cancer, highlighting the efficacy and safety of novel agents and combination therapies in both frontline and post-progression settings and the impact of these advancements on health care resource utilization and patient outcomes.

To view the article and claim CE credit for this activity, click here.

Program Description

This article provides a review of EGFR mutations and biomarker testing in non-small cell lung cancer (NSCLC), focusing on the clinical implications and therapeutic advancements. EGFR mutations are prevalent and drive tumor growth, necessitating precise biomarker testing for tailored treatment strategies. The article delves into the role of EGFR-targeted therapies, highlighting the efficacy and safety of novel and emerging agents and combination therapies in both frontline and post-progression settings, including the growing interest in investigational antibody-drug conjugates (ADCs) for patients with progressed disease. These therapies have shown significant improvements in efficacy and safety, but inconsistencies in biomarker testing persist. The importance of accurate and timely biomarker testing to guide treatment decisions, barriers to testing, and disparities in access and interpretation will also be discussed. Additionally, the article addresses the pharmacoeconomic considerations and resource utilization associated with EGFR-targeted therapies, examining factors such as adherence, molecular profiling, quality of life, health care resource utilization, and the cost implications of combination therapies. The role of the managed care pharmacist in formulary decision-making, payer strategies, and navigating challenges in biomarker testing will be examined, with a focus on the importance of optimizing resource utilization and ensuring patient access to appropriate therapies.


Type of Activity: Application
Release date: July 7, 2025
Expiration date: August 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Explain the role of biomarker testing in non-small cell lung cancer (NSCLC) and its impact on patient safety, treatment outcomes, and overall cost of care.
  • Analyze the results of key clinical trials investigating innovative treatment strategies for patients with EGFR mutation-positive metastatic NSCLC, including novel EGFR tyrosine kinase inhibitors, immunotherapy combinations, and other emerging therapies.
  • Examine the roles of oncology and managed care pharmacists in optimizing the use of targeted therapies in advanced EGFR-mutated NSCLC and implementing clinical pathways that enhance care quality, reduce variability, and promote cost-effective treatment strategies.
]]> Wed, 17 Sep 2025 02:08:19 +0000 tag:audioboom.com,2025-09-17:/posts/8778075 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 10: Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies https://audioboom.com/posts/8763514 10 Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies 2571 false full This article provides a comprehensive review of the latest clinical data supporting bispecific antibodies in lymphoma, their integration into earlier lines of therapy and combination regimens, and strategies for oncology pharmacists and managed care professionals to coordinate care and enhance patient safety.

To view the article and claim CE credit for this activity, click here.

Program Description

Bispecific antibodies (BsAbs) are revolutionizing the treatment of relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma by offering effective, off-the-shelf T-cell–redirecting therapies with manageable safety profiles. Pharmacists are integral in guiding treatment selection, supporting transitions of care, and contributing to the development of protocols and educational initiatives that ensure consistent, high-quality care across various institutions. This article provides a comprehensive review of the latest clinical data supporting BsAbs in lymphoma, their advantages over CAR T-cell therapies, and their integration into earlier lines of therapy and combination regimens. Best practices for managing unique toxicities, such as cytokine release syndrome, and coordinating care across inpatient and outpatient settings will also be discussed to equip oncology pharmacists and managed care professionals to optimize BsAb access, enhance patient safety, and improve cost-effectiveness.


Target Audience: Managed care pharmacists and oncology pharmacists
Type of Activity: Application
Release date: August 6, 2025
Expiration date: August 6, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours


Educational Objectives
At the completion of this activity, participants will be able to:

  • Examine the recent clinical data for new and emerging indications that incorporate bispecific antibodies (BsAbs) in the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
  • Explore the best practices for  supporting transitions of care and ensuring  safe and effective use of BsAbs in the  treatment of lymphoma.
  • Investigate innovative approaches in managed care to address logistical and operational hurdles, enabling broader access to BsAbs and improved clinical outcomes for patients.
]]> Fri, 15 Aug 2025 03:56:26 +0000 tag:audioboom.com,2025-08-15:/posts/8763514 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 9: Improving Patient Outcomes in Seasonal and Perennial Allergic Conjunctivitis https://audioboom.com/posts/8720375 9 Improving Patient Outcomes in Seasonal and Perennial Allergic Conjunctivitis 2726 false full This supplement will review the clinical and economic burdens associated with managing acute pain and explore opportunities to employ evidence-based guidelines that emphasize the prioritization of nonopioid therapies for acute pain conditions.

To view the article and claim CE credit for this activity, click here for pharmacists credit and click here for pharmacy technician credit.

Program Description

Allergic conjunctivitis is a common, noninfectious inflammation of the conjunctiva, the clear tissue covering the white parts of the eyes, that often coexists with allergic rhinitis and asthma, significantly impacting quality of life. Most cases can be managed in an outpatient setting by identifying and avoiding allergens, using nonpharmacologic approaches, and progressing to OTC ophthalmic treatments as needed. However, allergic conjunctivitis is frequently self-diagnosed or misdiagnosed, which results in suboptimal management. Pharmacists and pharmacy technicians, often the first point of contact for patients, play a crucial role in sharing education on the condition and treatment. This activity will review symptomatology, pathophysiology, and treatment recommendations. After participating, pharmacists and pharmacy technicians will be better equipped to provide accurate information and effective care, ultimately improving patient outcomes.


Target audience: Community pharmacists
Type of activity: Application
Release date: April 7, 2025
Expiration date: April 7, 2026
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free

Pharmacist Educational Objectives
At the completion of this activity, participants will be able to:

  • Explain the characteristics, symptoms, and allergens involved in seasonal and perennial allergic conjunctivitis
  • Distinguish the active ingredients, modes of action, and timing of various OTC ophthalmic medications for allergic conjunctivitis
  • Identify patients for suitable OTC treatments tailored to specific allergic conjunctivitis symptoms and personal factors

Pharmacy Technician Educational Objectives
At the completion of this activity, participants will be able to:

  • Explain the characteristics, symptoms, and allergens involved in seasonal and perennial allergic conjunctivitis
  • Distinguish the active ingredients, modes of action, and timing of various OTC ophthalmic medications for allergic conjunctivitis
  • Identify patients that would benefit from pharmacist counseling on suitable OTC treatments tailored to specific allergic conjunctivitis symptoms and personal factors
]]> Thu, 15 May 2025 00:12:00 +0000 tag:audioboom.com,2025-05-15:/posts/8720375 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 8: Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care https://audioboom.com/posts/8701261 8 Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care 4840 false full This supplement will review the clinical and economic burdens associated with managing acute pain and explore opportunities to employ evidence-based guidelines that emphasize the prioritization of nonopioid therapies for acute pain conditions.

To view the article and claim CE credit for this activity, click here.

Program Description

Acute pain carries a significant economic burden. Opioids, while often effective for short-term pain relief, contribute to this burden through potential long-term complications like addiction, overdose, and related health care utilization, increasing overall costs. Traditional nonopioid therapies, such as nonsteroidal anti-inflammatory drugs and acetaminophen, offer opportunities for potential long-term cost-effectiveness by minimizing these opioid-related complications. Emerging drugs that target voltage-gated sodium channels may offer opportunities to manage acute pain. Managed care professionals and pharmacists must consider emerging evidence for nonopioid therapies as well as guidelines for acute pain management to support balanced, patient-centered approaches with each treatment strategy. This supplement will explore the clinical and economic burdens associated with managing acute pain as well as opportunities to reduce health care utilization through evidence-based guidelines, such as CDC recommendations for acute pain management, that emphasize the prioritization of nonopioid therapies for acute pain management. Key managed care strategies, including formulary management, utilization management techniques, and legislative and operational strategies to promote access to nonopioid therapies, will be reviewed.


Target audience: Managed care pharmacists

Type of activity: Application
Release date: March 31, 2025
Expiration date: March 10, 2025

Time to complete activity: 2.0 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Examine the clinical and economic burden and challenges of managing acute pain within current treatment paradigms.
  • Analyze the clinical trial data on the efficacy and safety of novel nonopioid pain treatments, comparing them to traditional opioid therapies.
  • Investigate the unmet need and economic burden of acute pain management.
]]> Mon, 07 Apr 2025 15:18:00 +0000 tag:audioboom.com,2025-04-07:/posts/8701261 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 7: Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia https://audioboom.com/posts/8624682 7 Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia 5766 false full This supplement to The American Journal of Managed Care explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches.

To view the article and claim CE credit for this activity, click here.

Program Description

Although treatments for schizophrenia have improved in recent decades, many standard treatments still have significant limitations. Treating schizophrenia requires a personalized approach beyond just medication, including early intervention to improve outcomes and prevent relapse as well as care coordination to ensure adherence and symptom management. Both negative and cognitive symptoms are central aspects of schizophrenia treatment, but traditional antipsychotic medications have limited efficacy against these symptoms. Additionally, the lack of recently updated guidelines for managing therapies in patients with schizophrenia has created barriers to treatment. This supplement explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches. By facilitating appropriate use and access to emerging schizophrenia therapies, including prescription digital therapeutics, managed care professionals can play an important role in individualizing therapy and improving access to medications.


Target audience: Managed care pharmacists

Type of activity: Application
Release date: August 30, 2024
Expiration date: September 30, 2025

Time to complete activity: 3.0 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Explain positive, negative, and cognitive symptoms of schizophrenia and the unmet needs in the management of schizophrenia.
  • Explore the pharmacology, safety profiles, and clinical pearls of new and emerging therapies for the management of schizophrenia.
  • Analyze clinical trial data of recently approved and emerging therapies and how they fit into the treatment paradigm of schizophrenia.
  • Investigate value-based approaches to improve access to individualized treatment plans to address the clinical and economic burdens of disease.
]]> Mon, 16 Dec 2024 20:43:00 +0000 tag:audioboom.com,2024-12-16:/posts/8624682 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 6: Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements https://audioboom.com/posts/8608865 6 Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements 4262 false full This supplement will examine managed care considerations for prescription digital therapeutics in reducing treatment burden associated with schizophrenia. A social worker perspective interview accompanies this supplement and highlights opportunities for care coordination.

To view the article and claim CE credit for this activity, click here.

Program Description
Many patients with schizophrenia struggle with debilitating residual symptoms, treatment-related adverse effects, and difficulty with adherence to therapy as schizophrenia requires lifelong management, even when symptoms are not evident. Traditional treatment options for schizophrenia might require frequent in-person visits, which can increase treatment burden for patients or pose access barriers. Prescription digital therapeutics (PDTs) are emerging as a powerful tool for mental health conditions. This article will explore their potential use particularly in schizophrenia to alleviate negative symptoms, as well as in reducing the clinical and socioeconomic burden of the disorder. Managed care professionals should recognize the opportunity for PDTs to bridge gaps in care as a complementary tool by improving access to individualized and effective care. Yet, there remain challenges to PDTs, such as long-term patient utilization, establishing pathways for insurance coverage for digital interventions, and clinical practice guidance. This supplement reviews current treatments for psychotic (positive), negative, and cognitive symptoms and advantages and challenges in the use of emerging PDTs in schizophrenia care paradigms. A social worker perspective interview accompanies this supplement and highlights opportunities for care coordination, helping patients navigate the health care system, and providing other services and support to empower patients with schizophrenia to manage their illness and improve their quality of life.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: September 23, 2024
Expiration date: September 23, 2025
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Distinguish the characteristics of negative and cognitive symptoms associated with schizophrenia.
  • Explore the burden and treatment challenges of schizophrenia.
  • Examine the clinical data supporting the efficacy and safety of prescription digital therapeutics (PDTs) that target unmet needs in the management of schizophrenia.
  • Illustrate opportunities for managed care pharmacists to mitigate the clinical and economic impact of schizophrenia while enhancing access to emerging PDTs to alleviate negative and cognitive symptoms.
]]> Fri, 15 Nov 2024 03:00:00 +0000 tag:audioboom.com,2024-11-15:/posts/8608865 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 5: From Prescription Pad to Pharmacy Shelf: Unveiling the Future of Contraception https://audioboom.com/posts/8601368 5 From Prescription Pad to Pharmacy Shelf: Unveiling the Future of Contraception 2319 false full To view the article and claim CE credit for this activity, click here for pharmacists and click here for pharmacy technicians. 
Program Description
When counseling women about contraception, the choice of a contraceptive method is a complex decision that pharmacists play an integral role in by providing product information. The availability of an OTC contraception pill positions pharmacists for a greater role in contraceptive care within community practice settings. Though contraceptive pills have been available for decades, there are several differences between OTC and prescription birth control pills, like dosing schedules, adverse effects, and potential interactions with other medications that patients and pharmacists should be informed about. This article will examine the current state of contraception in the United States, the impact of increased access to contraception on reproductive health outcomes, and opportunities to remove barriers to the use of contraception with the OTC contraception pill. As the number of contraceptive options available continues to grow, it is essential that pharmacists use their skills to counsel and assist patients in decision-making to ensure they can decide upon an optimal method.

Target Audience: Community Pharmacists and Pharmacy Technicians

Type of Activity: Application
Release date: July 30, 2024
Expiration date: July 30, 2025
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

Pharmacists:

  • Analyze the public health impact of unintended pregnancy in the US
  • Identify social, economic, and regulatory barriers that limit access to contraception (including OTC options) for different patient populations
  • Differentiate OTC birth control pill options, including progestin-only and combination pills, considering factors such as efficacy, adverse effects, and patient suitability
  • Examine counseling on the proper use of and adherence to OTC birth control pills, including strategies for identifying and addressing potential adherence challenges
]]> This article will examine the current state of contraception in the United States, the impact of increased access to contraception on reproductive health outcomes, and opportunities to remove barriers to the use of contraception with the OTC contraception pill. Mon, 04 Nov 2024 17:07:00 +0000 tag:audioboom.com,2024-11-04:/posts/8601368 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 4: Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape https://audioboom.com/posts/8581366 4 Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape 4291 false full To view the article and claim CE credit for this activity, click here. 

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus that can substantially impact patients' quality of life. Early diagnosis and intervention are critical for mitigating the clinical burden of EoE and improving long-term prognosis. This supplement to The American Journal of Managed Care reviews recent advances in the treatment of EoE, focusing on the potential of recently approved therapies to improve patient outcomes. Data from recent clinical trials and updated guideline recommendations highlight the progress made in targeting the histology and symptomatology of the disease. Important managed care considerations, including financial challenges and treatment access issues, that arise from the introduction of these novel therapies will be examined. Pharmacists and managed care professionals will gain insights into the inflammatory process of EoE and the importance of early treatment while optimizing health care resource utilization. The article provides an analysis of clinical data to support the safe and effective use of new therapies, as well as potential opportunities for improving treatment decision-making and resource allocation in the management of EoE. ]]> Wed, 02 Oct 2024 19:52:00 +0000 tag:audioboom.com,2024-10-02:/posts/8581366 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 3: Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals https://audioboom.com/posts/8544957 3 Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals 2100 false full To view the article and claim CE credit for this activity, click here. 

In the United States, almost half of cancers are preventable, and early detection would allow for cancer treatment to be more effective both in cost and patient outcomes; however, established cancer screening tools are underutilized. Blood-based technologies, known as multi-cancer early detection (MCED) tests, can identify multiple cancers early and simultaneously. As more is revealed about the significance of early cancer detection, it becomes evident that MCED tests not only promise to enhance patient outcomes, but can also optimize health care resource allocation and reduce the socioeconomic burden of cancer. When utilized appropriately, these MCED technologies have the potential to detect a higher proportion of early-stage treatment-amenable cancers. It is imperative that managed care professionals are educated about the recent and ongoing advancements in the field of oncology to spearhead the integration of MCED technologies into care of cancers that do not have a screening method and are often diagnosed in advanced stages. This activity will provide managed care professionals with the tools and resources needed to identify and address the various barriers and health disparities that contribute to low rates of cancer screenings, offer a deeper insight into the cost-effectiveness of novel MCED tests, and equip them with knowledge of the clinical and economic benefits associated with early cancer detection and treatment. ]]> Mon, 22 Jul 2024 13:41:00 +0000 tag:audioboom.com,2024-07-22:/posts/8544957 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 2: Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults https://audioboom.com/posts/8542419 2 Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults 2628 false full To view the article and to claim credit for completing this CE activity, please CLICK HERE. 

Respiratory syncytial virus (RSV) is a common virus that primarily presents as upper respiratory infection but can develop in a significant number of patients as lower respiratory tract illness with complications including hospitalization and death. The risk of RSV complications is increased in adults aged 50 years and older, and without an FDA-approved treatment for RSV, pharmacists should advise patients of supportive care and prevention strategies including vaccination. This article will review clinical safety and efficacy data of RSV vaccine candidates currently in development for the older adult population. Factors contributing to disparities in adult vaccination rates and the role of the pharmacist in sharing evidence-based information about emerging vaccines and providing counseling and education to address barriers to vaccination will also be examined through patient counseling video vignettes. This article is additionally available as a recorded audiobook.  ]]> Tue, 16 Jul 2024 17:53:00 +0000 tag:audioboom.com,2024-07-16:/posts/8542419 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts 1: Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Pharmacists https://audioboom.com/posts/8542413 1 Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Pharmacists 2544 false full To view the article and claim CE credit for completing this activity, please CLICK HERE. 

Adults with chronic behavioral health illnesses, such as bipolar disorder, face many challenges and barriers in receiving appropriate health care services and treatment. Complicating the management of bipolar disorder is its presentation with mixed features, including comorbid anxiety, or concurrent symptoms of depression and mania/hypomania. This activity reviews diagnostic criteria for bipolar disorder with mixed features as well as treatment challenges that include a limited patient response to available therapies and a risk for mood switching with therapies that are targeted towards only one set of symptoms. It is important for pharmacists to be familiar with current treatment guideline recommendations for the treatment of bipolar disorder with mixed features and to be able to differentiate between antipsychotic therapy options, including their safety and efficacy profiles. This article provides practical information that pharmacists can refer to when counseling patients with bipolar disorder on drug administration and expectations, providing recommendations for optimizing adherence and addressing missed doses, minimizing potential drug interactions, and managing common adverse effects.  ]]> Tue, 16 Jul 2024 17:48:00 +0000 tag:audioboom.com,2024-07-16:/posts/8542413 PTCE Pharmacy SoundScripts PTCE Pharmacy SoundScripts